Fierce Pharma While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO cut to the chase this week in a blatant rebuke of HHS secretary Robert F. Kennedy Jr., according to The Wall Street Journal.
“I have very productive discussions when it comes to cancer cures, when it comes to the ‘most-favored nations’ deal, et cetera,” Pfizer’s Albert Bourla said during a WSJ event at the World Economic Forum in Davos, Switzerland.
“It’s a different world when you start discussing vaccines, there’s almost like a religion there,” the CEO said, as quoted by the newspaper.